OBJECTIVE: To examine the threshold in disease activity associated with switching biologic treatment regimens in rheumatoid arthritis (RA) patients in real-world clinical practice. METHODS: Using data from a prospective observational North American cohort of RA patients through December 30, 2009, patients who initiated a new anti-tumor necrosis factor α (anti-TNFα) agent with ≥6 months of followup were identified. Patients were classified as switchers or maintainers depending on whether they continued their anti-TNF treatment or switched (including discontinuation) within 12 months. Level of disease activity measured by the Clinical Disease Activity Index (CDAI) and Disease Activity Score in 28 joints (DAS28) at the time of the switch (corresponding followup visit for maintainers) was examined and random-effect multivariable logistic regression was used to adjust for covariates. RESULTS: Mean age and RA duration among 1,549 eligible patients were 56.1 and 9.6 years, respectively, 80% were women, 62% were initiating their first biologic, and 30% were initiating their second biologic. At the time of the switch, the median DAS28 and CDAI score were 3.1 and 8.4 among maintainers and 4.0 and 15.2 among switchers, respectively. Maintainers also experienced a greater amount of reduction in disease activity compared with switchers (CDAI: -7.7 versus -2.3, DAS28: -1.1 versus -0.3). The threshold to switch decreased over calendar time, with the greatest amount of reduction observed among patients with moderate disease activity. CONCLUSION: On average, physicians and patients were willing to continue biologic treatment for patients who were at or near low disease activity. The threshold to switch decreased over time, especially among partial responders.
OBJECTIVE: To examine the threshold in disease activity associated with switching biologic treatment regimens in rheumatoid arthritis (RA) patients in real-world clinical practice. METHODS: Using data from a prospective observational North American cohort of RApatients through December 30, 2009, patients who initiated a new anti-tumor necrosis factor α (anti-TNFα) agent with ≥6 months of followup were identified. Patients were classified as switchers or maintainers depending on whether they continued their anti-TNF treatment or switched (including discontinuation) within 12 months. Level of disease activity measured by the Clinical Disease Activity Index (CDAI) and Disease Activity Score in 28 joints (DAS28) at the time of the switch (corresponding followup visit for maintainers) was examined and random-effect multivariable logistic regression was used to adjust for covariates. RESULTS: Mean age and RA duration among 1,549 eligible patients were 56.1 and 9.6 years, respectively, 80% were women, 62% were initiating their first biologic, and 30% were initiating their second biologic. At the time of the switch, the median DAS28 and CDAI score were 3.1 and 8.4 among maintainers and 4.0 and 15.2 among switchers, respectively. Maintainers also experienced a greater amount of reduction in disease activity compared with switchers (CDAI: -7.7 versus -2.3, DAS28: -1.1 versus -0.3). The threshold to switch decreased over calendar time, with the greatest amount of reduction observed among patients with moderate disease activity. CONCLUSION: On average, physicians and patients were willing to continue biologic treatment for patients who were at or near low disease activity. The threshold to switch decreased over time, especially among partial responders.
Authors: Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans Journal: Arthritis Rheum Date: 2005-11
Authors: Mark C Genovese; Jean-Claude Becker; Michael Schiff; Michael Luggen; Yvonne Sherrer; Joel Kremer; Charles Birbara; Jane Box; Kannan Natarajan; Isaac Nuamah; Tracy Li; Richard Aranda; David T Hagerty; Maxime Dougados Journal: N Engl J Med Date: 2005-09-15 Impact factor: 91.245
Authors: Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen Journal: Arthritis Res Ther Date: 2005-04-07 Impact factor: 5.156
Authors: Leslie R Harrold; Bradley S Stolshek; Sabrina Rebello; David H Collier; Alex Mutebi; Sally W Wade; Wendi Malley; Jeffrey D Greenberg; Carol J Etzel Journal: Clin Rheumatol Date: 2017-03-07 Impact factor: 2.980
Authors: Devin Incerti; Jeffrey R Curtis; Jason Shafrin; Darius N Lakdawalla; Jeroen P Jansen Journal: Pharmacoeconomics Date: 2019-06 Impact factor: 4.981
Authors: Iris Navarro-Millán; Anne Zinski; Sally Shurbaji; Bernadette Johnson; Liana Fraenkel; James Willig; Maria I Danila; Huifeng Yun; Jeffrey R Curtis; Monika M Safford Journal: Arthritis Care Res (Hoboken) Date: 2019-01 Impact factor: 4.794
Authors: J R Curtis; S Yang; L Chen; J E Pope; E C Keystone; B Haraoui; G Boire; J C Thorne; D Tin; C A Hitchon; C O Bingham; V P Bykerk Journal: Arthritis Care Res (Hoboken) Date: 2015-10 Impact factor: 4.794
Authors: Jeffrey R Curtis; Lang Chen; Jeffrey D Greenberg; Leslie Harrold; Meredith L Kilgore; Joel M Kremer; Daniel H Solomon; Huifeng Yun Journal: Pharmacoepidemiol Drug Saf Date: 2016-12-28 Impact factor: 2.890
Authors: Paul R Falzer; Howard L Leventhal; Ellen Peters; Terri R Fried; Robert Kerns; Marion Michalski; Liana Fraenkel Journal: Pain Pract Date: 2012-07-02 Impact factor: 3.183
Authors: Jeffrey R Curtis; John W Baddley; Shuo Yang; Nivedita Patkar; Lang Chen; Elizabeth Delzell; Ted R Mikuls; Kenneth G Saag; Jasvinder Singh; Monika Safford; Grant W Cannon Journal: Arthritis Res Ther Date: 2011-09-20 Impact factor: 5.156
Authors: Anat Fisher; Ken Bassett; James M Wright; M Alan Brookhart; Hugh Freeman; Colin R Dormuth Journal: PLoS One Date: 2014-08-20 Impact factor: 3.240
Authors: Anat Fisher; Ken Bassett; James M Wright; M Alan Brookhart; Hugh J Freeman; Colin R Dormuth Journal: BMJ Open Date: 2014-09-30 Impact factor: 2.692